US Dollar vs MXN

Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.

Regístrate

ROIV Roivant Sciences Ltd

10.69

0.00 (0.00%)

Pre Mercado

Última actualización: 07:31:51

Retrasado por 15 minutos

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Roivant Sciences (NASDAQ:ROIV)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Haga Click aquí para más Gráficas Roivant Sciences.

Roivant Sciences (NASDAQ:ROIV)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024

Haga Click aquí para más Gráficas Roivant Sciences.

Noticias sobre Roivant Sciences Ltd ROIV

Form 4 - Statement of changes in beneficial ownership of securities
Jueves 30 de Mayo 2024 (4 semanas hace) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Jueves 30 de Mayo 2024 (4 semanas hace) • Edgar (US Regulatory)

Form 8-K - Current report
Jueves 30 de Mayo 2024 (4 semanas hace) • Edgar (US Regulatory)

Form 8-K - Current report
Jueves 30 de Mayo 2024 (4 semanas hace) • Edgar (US Regulatory)

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
Jueves 30 de Mayo 2024 (4 semanas hace) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 22 de Mayo 2024 (1 mes hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 22 de Mayo 2024 (1 mes hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 22 de Mayo 2024 (1 mes hace) • Edgar (US Regulatory)

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
Jueves 16 de Mayo 2024 (1 mes hace) • GlobeNewswire Inc.

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Martes 2 de Abril 2024 (3 meses hace) • GlobeNewswire Inc.

Roivant Sciences Set to Join S&P MidCap 400; Sunrun to Join S&P SmallCap 600
Martes 26 de Marzo 2024 (3 meses hace) • PR Newswire (US)

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update
Martes 13 de Febrero 2024 (4 meses hace) • GlobeNewswire Inc.

Más de Roivant Sciences Ltd Artículos de Noticias

Deutsche Telekom (QX)

Invesco QQQ Trust Series 1

Energy Select Sector SPDR

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones